Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | CTSV | O60911 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3861678 | 0.88 | ALDH1A1 (0.62) | ALDH1A1CYP3A4TDP1ALOX15KMT2A | |
| SCHEMBL2728411 | 0.83 | ALDH1A1 (0.58) | ALDH1A1CYP3A4TDP1ALOX15KMT2A | |
| SCHEMBL28835860 | 0.83 | TP53 (0.52) | ALDH1A1CYP3A4TDP1ALOX15KMT2A | |
| SCHEMBL5240597 | 0.82 | ALDH1A1 (0.62) | ALDH1A1CYP3A4TDP1ALOX15KMT2A | |
| SCHEMBL19969740 | 0.81 | ALDH1A1 (0.60) | ALDH1A1CYP3A4TDP1ALOX15KMT2A | |
| SCHEMBL30309481 | 0.79 | ALDH1A1 (0.54) | ALDH1A1CYP3A4TDP1ALOX15KMT2A | |
| SCHEMBL1644599 | 0.76 | ALDH1A1 (0.58) | ALDH1A1CYP3A4TDP1ALOX15KMT2A | |
| SCHEMBL7920060 | 0.76 | PDE7A (0.60) | ALDH1A1CYP3A4TDP1ALOX15KMT2A | |
| SCHEMBL21939455 | 0.76 | CSNK2A1 (0.47) | ALDH1A1ALOX15KMT2AMAPTTP53 | |
| SCHEMBL7919799 | 0.75 | PTGES (0.60) | ALDH1A1CYP3A4TDP1ALOX15KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223299-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | REGENERON PHARMACEUTICALS, INC. | 2025-07-10 | — | — | US | disclosed |
| US-12297207-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | REGENERON PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| CN-115645543-A | Maytansinoid derivatives, conjugates thereof, and methods of use | 里珍纳龙药品有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-20220259225-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | REGENERON PHARMACEUTICALS, INC. | 2022-08-18 | — | — | US | disclosed |
| US-20200385402-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | REGENERON PHARMACEUTICALS, INC. | 2020-12-10 | — | — | US | disclosed |
| EP-3273998-B1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | REGENERON PHARMA (US) | 2019-09-04 | — | — | EP | disclosed |
| EP-3273998-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | Regeneron Pharmaceuticals, Inc. (US) | 2018-01-31 | — | — | EP | disclosed |
| US-20160375147-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | REGENERON PHARMACEUTICALS, INC. | 2016-12-29 | — | — | US | disclosed |
| WO-2016160615-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | REGENERON PHARMACEUTICALS, INC. (US) | 2016-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160375147-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | SLC10A1, HNMT, OGFR | ALDH1A1 317/4885CYP3A4 1529/4885TDP1 1130/4885 |
| US-20250223299-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | SLC10A1, HNMT, OGFR | ALDH1A1 317/4885CYP3A4 1529/4885TDP1 1130/4885 |
| US-20200385402-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | SLC10A1, HNMT, OGFR | ALDH1A1 317/4885CYP3A4 1529/4885TDP1 1130/4885 |
| US-12297207-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | SLC10A1, HNMT, OGFR | ALDH1A1 317/4885CYP3A4 1529/4885TDP1 1130/4885 |
| US-20220259225-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | SLC10A1, HNMT, OGFR | ALDH1A1 317/4885CYP3A4 1529/4885TDP1 1130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.